BioWorld Asia

Aug. 18, 2004

Evolva Raises EUR12M To Drive Molecular Evolution Platform

Evolva SA raised €12 million in a Series A round to further develop its Watchmaker platform, which employs yeast artificial chromosomes and flow cytometry for the synthesis and selection of novel compounds. (BioWorld International) Read More

UK Clears Cloning Embryos For Extraction Of Stem Cells

Immune System Genes Merge To Beat Back Hepatitis C Virus

Lynx, Solexa Eyeing Merger After Gaining DNA Clusters

TopoTarget, NeuroSearch Form Agreement Around Cancer Drug

New Faces Constructing New EU Biotechnology Guidelines

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 11, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...